Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
More Information Supplier PageBaricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
More Information Supplier PageBaricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).
More Information Supplier PageBLY719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
More Information Supplier PageBLY719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
More Information Supplier PageBLY719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
More Information Supplier PageBLY719 is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
More Information Supplier PageSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.
More Information Supplier PageSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.
More Information Supplier PageSkepinone-L is a selective p38 mitogen-activated protein kinase inhibitor.
More Information Supplier Page
